Study title: S2CQ30 A multicentre placebo-controlled study on the efficacy and safety of oral sumatriptan (100mg) in the treatment of migraine in adolescents.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Nervous System Diseases [C10] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: SUMATRIPTAN | |||||
ATC code: N02CC01 | |||||
Document link: Study S2CQ30(SUM9291)-Sumatriptan-Imigranxlsx.xls | |||||
Document date: 2011-10-20 | |||||
Study number: SUM9291 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | Y |